Oral Treatment with BT-11 Ameliorates Inflammatory Bowel Disease by Enhancing Regulatory T Cell Responses in the Gut

by NImmune Biopharma | May 2, 2023 | Research and White Papers

Inflammatory bowel disease (IBD) is an expanding autoimmune disease afflicting millions that remains difficult to treat due to the accumulation of multiple immunological changes. BT-11 is an investigational new drug for IBD that is orally active, gut restricted, and...

The Safety, Tolerability, and Pharmacokinetics Profile of BT-11, an Oral, Gut-Restricted Lanthionine Synthetase C-Like 2 Agonist Investigational New Drug for Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial

by NImmune Biopharma | May 2, 2023 | Research and White Papers

BT-11 is a new oral, gut-restricted, first-in-class investigational drug for Crohn disease (CD) and ulcerative colitis (UC) that targets the lanthionine synthetase C-like 2 (LANCL2) pathway and immunometabolic mechanisms. Oral BT-11 was assessed for safety,...

First-in-class topical therapeutic omilancor ameliorates disease severity and inflammation through activation of LANCL2 pathway in psoriasis

by NImmune Biopharma | May 2, 2023 | Research and White Papers

Psoriasis (PsO) is a complex immune-mediated disease that afflicts 100 million people. Omilancor is a locally-acting, small molecule that selectively activates the Lanthionine Synthetase C-like 2 (LANCL2) pathway, resulting in immunoregulatory effects at the...

NImmune Biopharma Launches with Phase III-Ready Asset Gained from Landos Biopharma

by NImmune Biopharma | Mar 22, 2023 | News

Virginia life sciences entrepreneur Josep Bassaganya-Riera’s latest company NImmune Biopharma launched with an eye on a potential New Drug Application for its Phase III-ready experimental therapeutic for ulcerative colitis. NImmune Biopharma’s lead asset is...

Josep Bassaganya-Riera Launches NImmune Biopharma with Phase 3-Ready Clinical Candidate Omilancor for the Treatment of Ulcerative Colitisand Crohn’s Disease

by NImmune Biopharma | Mar 22, 2023 | Press Release

Download Press Release — Led by Dr. Bassaganya-Riera and a team of seasoned industry executives, NImmune is developing later-stage precision therapies addressing multiple autoimmune diseases, starting with Ulcerative Colitis (UC) and Crohn’s disease (CD) — NImmune’s...